No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $7
Cantor Fitzgerald Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Cuts Target Price to $14
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7
X4 Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)
X4 Pharmaceuticals' Earnings Call: Progress Amid Challenges